SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2011 / Cilt: 41 - Sayı: 3

Obstruktif uyku apne sendromlu hastalarda metabolik profi l ve insülin direnci

Metabolic profi le and insulin resistance in patients with obstructive sleep apnea syndrome

Şahin ÖĞREDEN
Hale ARAL
Özgür YİĞİT
Güvenç GÜVENEN
Berrin BERÇİK İNAL
Mustafa ŞAHİN
Pages
443–454
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

OSAS patients with metabolic syndrome and insulin resistance are at an increased risk of diabetes mellitus and cardiovascular diseases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Th e following metabolic parameters were assessed in patients with obstructive sleep apnea syndrome (OSAS) diagnosed by polysomnography (PSG): leptin, IFG (ımpaired fasting glucose), thyroid functions, thyroid autoantibodies, lipid parameters, insulin levels, HOMA-IR index, CRP, obesity, and metabolic syndrome frequency.
📊
Key Findings & Data:Materials and methods: Th ree patient groups were defi ned based on apnea-hypoapnea index (AHI) levels (Group I: n: 11 male (M)/19 female (F); Group II: n: 19 M/10 F; Group III: n: 21 M/10 F) and 2 control groups (obese (n = 18 M/12 F) and normal (n = 12 M/18 F)) were included with comparable BMI value and age.
💡
Conclusion & Impact:OSAS patients with metabolic syndrome and insulin resistance are at an increased risk of diabetes mellitus and cardiovascular diseases.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Th e following metabolic parameters were assessed in patients with obstructive sleep apnea syndrome (OSAS) diagnosed by polysomnography (PSG): leptin, IFG (ımpaired fasting glucose), thyroid functions, thyroid autoantibodies, lipid parameters, insulin levels, HOMA-IR index, CRP, obesity, and metabolic syndrome frequency. Materials and methods: Th ree patient groups were defi ned based on apnea-hypoapnea index (AHI) levels (Group I: n: 11 male (M)/19 female (F); Group II: n: 19 M/10 F; Group III: n: 21 M/10 F) and 2 control groups (obese (n = 18 M/12 F) and normal (n = 12 M/18 F)) were included with comparable BMI value and age. Results: Th e frequencies of metabolic syndrome were compared between patient groups, and no signifi cant diff erence was found, despite an increased frequency of metabolic syndrome from mild OSAS to severe OSAS. Th e following signifi cant diff erences were observed for insulin values: normal controls versus obese controls (P < 0.0001), normal controls versus Group I (P = 0.014), normal controls versus Group II (P = 0.001), normal controls versus Group III (P < 0.0001), and Group I versus Group III (P = 0.026). Conclusion: An increased frequency of metabolic syndrome and insulin resistance was found in OSAS patients. OSAS patients with metabolic syndrome and insulin resistance are at an increased risk of diabetes mellitus and cardiovascular diseases.

Özet

Amaç: Bu çalışmada polisomnografi ile obstruktif uyku apne sendromu (OSAS) teşhisi konmuş hastaların aşağıda belirtilen metabolik parametreleri değerlendirildi: leptin, bozulmuş açlık glukozu, tiroid fonksiyonları, tiroid otoantikorları, lipid parametreleri, insülin seviyeleri, HOMA-IR indeks, obezite, ve metabolik sendrom sıklığı. Yöntem ve gereç: Apne-hipoapne indeksi (AHI) temel alınarak 3 hasta grubu (Grup I: n: 11 Erkek (E)/ 19 Kadın (K); Grup II: n: 19 E/10 K; Grup III: n: 21 E/10 K) ve vücut kitle indeksi (BMI) değeri ve yaş karşılaştırılmasını içeren iki kontrol grubu (obez (n = 18 E/12 K) ve normal (n = 12E/18K)) tanımlandı. Bulgular: Metabolik sendrom sıklığı hafi f OSAS’dan ciddi OSAS’ a doğru artmasına rağmen hasta grupları arasında anlamlı farklılık bulunamadı. İnsülin değerleri için farklılıklar gözlendi: normal kontrol obez kontrol karşısında (P < 0,0001): normal kontrol Grup I karşısında (P = 0,014); normal kontrol Grup II karşısında (P = 0,001); normal kontrol Grup III karşısında ( P < 0,0001); Grup I Grup III karşısında (P < 0,026).Sonuç: OSAS’lı hastalarda artan metabolik sendrom sıklığı ve artan insülin direnci bulundu. Metabolik sendromlu ve insülin direnci olan hastalarda diabetes mellitus ve kardiyovasküler hastalık riski artmıştır.

🔖

Cite This Article

ÖĞREDEN, Ş., ARAL, H., YİĞİT, Ö., GÜVENEN, G., İNAL, B. B., ŞAHİN, M. (2022). Obstruktif uyku apne sendromlu hastalarda metabolik profi l ve insülin direnci. Turkish Journal of Medical Sciences, Cilt: 41 - Sayı: 3, 443–454. https://ajindex.com/articles/611405

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Guilleminault C, Tilkian A, Dement WC. Th e sleep apnea syndromes. Ann Rev Med 1976; 27: 465-484
  2. Guilleminault C, van den Hoed J, Mitler MM. Clinical overview of the sleep apnea syndromes. New York: Alan R Liss 1978; 1-12
  3. Kales A, Caldwell A, Cadieux R, Vela-Bueno A, Ruch L, Mayers S. Severe obstructive sleep apnea-II: Associated psychopathology and psychosocial consequences. J Chron Dis 1985; 38: 427-434
  4. Köktürk O. Uykunun izlenmesi. Normal uyku. Tüberküloz ve Toraks 1999; 47: 372-380
  5. Lin CC, Tsan KW, Chen PJ. Th e relationship between sleep apnea syndrome and hypothyroidism. Chest 1992; 102: 1663-7
  6. Popovici I, Khawaja I. Effi cacy of thyroid function tests in patients suspected of having obstructive sleep apnea. Chest 1997; 112: 149S
  7. Winkelman JW, Goldman H, Piscatelli N, Lukas S, Dorsey CM, Cunningham S. Are thyroid function tests necessary in patients with suspected sleep apnea? Sleep 1996; 19: 790-3
  8. Skjodt NM, Atkar R, Easton PA. Screening for hypothyroidism in sleep apnea. Am J Respir Crit Care Med 1999; 160: 732.5 9. Wolk R, Shamsuzzaman ASM, Somers VK. Obesity, Sleep Apnea and Hypertension. Hypertension 2003; 42; 1067-1074 10. Koskenvuo M, Kaprio J, Partinen M, Langinvainio H, Sarna S, Heikkila K. Snoring as a risk factor for hypertension and angina pectoris. Lancet 1985; 1: 893-6
  9. Baguet JP, Narkiewicz K, Mallion JM. Update on Hypertension Management: obstructive sleep apnea and hypertension. J Hypertens 2006; 24: 205-8
  10. Wolk R, Shamsuzzaman ASM, Somers VK. Obesity, Sleep Apnea and Hypertension. Hypertension 2003; 42; 1067-1074
  11. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH, Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101: 1767-72
  12. Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003; 107: 1129-34
  13. Guilleminault C, Kirisoglu C, Ohayon MM. C-reactive protein and sleep-disordered breathing. Sleep 2004; 27: 1507-11
  14. Shamsuzzaman AS, Winnicki M, Lanfranchi P, Wolk R, Kara T, Accurso V et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105: 2462-2464
  15. Reichmuth KJ, Austin D, Skatrud JB, Young T. Association of sleep apnea and type II diabetes: a population-based study. Am